Podcast #655 · 16 Jun 2026
Managing Large Liver Tumors: Strategies & Challenges
- Multidisciplinary Care
- Radiation Segmentectomy
- Y90 Radioembolization
- Immunotherapy
- Hepatocellular Carcinoma (HCC)
- Interventional Oncology (IO)
- Tumor Board
- Interventional Radiology (IR)
- Biliary Stricture
- 2026 HCC Creator Weekend™
How is Y90 radioembolization rewriting the rules for managing large HCC tumors and creating new curative-intent therapeutic pathways where palliation was once deemed the only option? In this episode of the 2026 HCC Creator Weekend™, interventional radiologists Dr. Chris Malone (WashU), Dr. Tyler Sandow (Ochsner Health), and Dr. Beau Toskich (Mayo Clinic Florida) join host Dr. Zach Berman for a case-based discussion on advanced dosimetric strategies and embolization approaches for large and complex HCC lesions.
This podcast is supported by an educational grant from Boston Scientific.
Timestamps
Resources
- Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
- TheraSphere With Durvalumab and Tremelimumab for HCC (ROWAN)
- Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
- Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium